Literature DB >> 26403201

The MEF2-HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro.

Andrea Clocchiatti1, Eros Di Giorgio1, Giulia Viviani1, Charles Streuli2, Andrea Sgorbissa1, Raffaella Picco1, Valentina Cutano1, Claudio Brancolini3.   

Abstract

The myocyte enhancer factor 2 and histone deacetylase (MEF2-HDAC) axis is a master regulator of different developmental programs and adaptive responses in adults. In this paper, we have investigated the contribution of the axis to the regulation of epithelial morphogenesis, using 3D organotypic cultures of MCF10A cells as a model. We have demonstrated that MEF2 transcriptional activity is upregulated during acini formation, which coincides with exit from the proliferative phase. Upregulation of the transcription of MEF2 proteins is coupled to downregulation of HDAC7, which occurs independently from changes in mRNA levels, and proteasome- or autophagy-mediated degradation. During acini formation, the MEF2-HDAC axis contributes to the promotion of cell cycle exit, through the engagement of the CDK inhibitor CDKN1A. Only in proliferating cells can HDAC7 bind to the first intron of the CDKN1A gene, a region characterized by epigenetic markers of active promoters and enhancers. In cells transformed by the oncogene HER2 (ERBB2), acini morphogenesis is altered, MEF2 transcription is repressed and HDAC7 is continuously expressed. Importantly, reactivation of MEF2 transcriptional activity in these cells, through the use of a HER2 inhibitor or by enhancing MEF2 function, corrected the proliferative defect and re-established normal acini morphogenesis.
© 2015. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  3D culture; Apoptosis; Breast cancer; CDKN1A; Cell cycle; ERBB2; H3K27; HDAC4; HDAC5; HDAC7; HER2; Lapatinib; MEF2A; MEF2D; Morphogenesis; p21

Mesh:

Substances:

Year:  2015        PMID: 26403201     DOI: 10.1242/jcs.170357

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  9 in total

1.  Multi-target weapons: diaryl-pyrazoline thiazolidinediones simultaneously targeting VEGFR-2 and HDAC cancer hallmarks.

Authors:  Neha Upadhyay; Kalpana Tilekar; Sabreena Safuan; Alan P Kumar; Markus Schweipert; Franz-Josef Meyer-Almes; Ramaa C S
Journal:  RSC Med Chem       Date:  2021-07-27

2.  HDAC4 degradation during senescence unleashes an epigenetic program driven by AP-1/p300 at selected enhancers and super-enhancers.

Authors:  Eros Di Giorgio; Harikrishnareddy Paluvai; Emiliano Dalla; Liliana Ranzino; Alessandra Renzini; Viviana Moresi; Martina Minisini; Raffaella Picco; Claudio Brancolini
Journal:  Genome Biol       Date:  2021-05-10       Impact factor: 13.583

3.  Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells.

Authors:  Sean M Holloran; Bakhtiyor Nosirov; Katherine R Walter; Gloria M Trinca; Zhao Lai; Victor X Jin; Christy R Hagan
Journal:  Mol Cell Endocrinol       Date:  2020-05-11       Impact factor: 4.102

4.  The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness.

Authors:  Eros Di Giorgio; Elisa Franforte; Sebastiano Cefalù; Sabrina Rossi; Angelo Paolo Dei Tos; Monica Brenca; Maurizio Polano; Roberta Maestro; Harikrishnareddy Paluvai; Raffaella Picco; Claudio Brancolini
Journal:  PLoS Genet       Date:  2017-04-18       Impact factor: 5.917

5.  HDAC7-mediated control of tumour microenvironment maintains proliferative and stemness competence of human mammary epithelial cells.

Authors:  Valentina Cutano; Eros Di Giorgio; Martina Minisini; Raffaella Picco; Emiliano Dalla; Claudio Brancolini
Journal:  Mol Oncol       Date:  2019-06-27       Impact factor: 6.603

6.  Missense substitutions at a conserved 14-3-3 binding site in HDAC4 cause a novel intellectual disability syndrome.

Authors:  Emma Wakeling; Meriel McEntagart; Michael Bruccoleri; Charles Shaw-Smith; Karen L Stals; Matthew Wakeling; Angela Barnicoat; Clare Beesley; Andrea K Hanson-Kahn; Mary Kukolich; David A Stevenson; Philippe M Campeau; Sian Ellard; Sarah H Elsea; Xiang-Jiao Yang; Richard C Caswell
Journal:  HGG Adv       Date:  2021-01-14

7.  VPS39-deficiency observed in type 2 diabetes impairs muscle stem cell differentiation via altered autophagy and epigenetics.

Authors:  Cajsa Davegårdh; Johanna Säll; Anna Benrick; Christa Broholm; Petr Volkov; Alexander Perfilyev; Tora Ida Henriksen; Yanling Wu; Line Hjort; Charlotte Brøns; Ola Hansson; Maria Pedersen; Jens U Würthner; Klaus Pfeffer; Emma Nilsson; Allan Vaag; Elisabet Stener-Victorin; Karolina Pircs; Camilla Scheele; Charlotte Ling
Journal:  Nat Commun       Date:  2021-04-23       Impact factor: 14.919

8.  HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation.

Authors:  Ya Gao; Yangdan Liu; Danning Zheng; Chiakang Ho; Dongsheng Wen; Jiaming Sun; Lu Huang; Yuxin Liu; Qingfeng Li; Yifan Zhang
Journal:  Int J Biol Sci       Date:  2022-09-11       Impact factor: 10.750

9.  The nuclear receptor ERβ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading.

Authors:  Roberta Tarallo; Giorgio Giurato; Giuseppina Bruno; Maria Ravo; Francesca Rizzo; Annamaria Salvati; Luca Ricciardi; Giovanna Marchese; Angela Cordella; Teresa Rocco; Valerio Gigantino; Biancamaria Pierri; Giovanni Cimmino; Luciano Milanesi; Concetta Ambrosino; Tuula A Nyman; Giovanni Nassa; Alessandro Weisz
Journal:  Genome Biol       Date:  2017-10-06       Impact factor: 13.583

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.